Skip to content

Addiction: all studies

Page 85 of 859: studies 841 to 850 of 8,590, newest first. Back to the addiction overview

Research

Behavioral metabolomics: how behavioral data can guide metabolomics research on neuropsychiatric disorders.

Metabolomics : Official journal of the Metabolomic Society August 2, 2023 Ross Van de Wetering, Jan A Vorster, Sophie Geyrhofer et al. 4 citations

Metabolomics produces vast quantities of data but determining which metabolites are the most relevant to the disease or disorder of interest can be challenging. This study sought to demonstrate how behavioral models of psychiatric disorders can be combined with metabolomics research to overcome this limitation. We designed a preclinical, untargeted metabolomics procedure, that focuses on the...

Δ9 -Tetrahydrocannabinol self-administration induces cell type-specific adaptations in the nucleus accumbens core.

Addiction Biology August 2023 Constanza Garcia-Keller, Madeline Hohmeister, Kailyn Seidling et al.

Drugs of abuse induce cell type-specific adaptations in D1- and D2-medium spiny neurons (MSNs) in the nucleus accumbens core (NAcore) that can bias signalling towards D1-MSNs and enhance relapse vulnerability. Whether Δ9 -tetrahydrocannabinol (THC) use initiates similar neuroadaptations is unknown. D1- and D2-Cre transgenic rats were transfected with Cre-dependent reporters and trained to...

The current state of ayahuasca research in animal models: A systematic review.

Progress in Neuro-Psychopharmacology and Biological Psychiatry July 13, 2023 Dimitri Daldegan-Bueno, Natalia Maria Simionato, Vanessa Manchim Favaro et al. 18 citations

The psychedelic brew ayahuasca is increasingly being investigated for its therapeutic potential. Animal models are essential to investigate the pharmacological effects of ayahuasca since they can control important factors influencing it, such as the set and setting. Review and summarise data available on ayahuasca research using animal models. We systematically searched five databases (PubMed,...

Psychoactive substances in psychotherapy - A vision for the future? – A systematic review on Psilocybin

July 6, 2023 Jenny Tetem, Tamara Fischmann, Tim Julian Möller preprint

This work is a literature review on the use of psilocybin in psychotherapeutic treatment of mental illnesses. The review answers the question of what opportunities and risks are associated with the use of the psychoactive substance psilocybin. Peer-reviewed studies between 2017 and 2022 were included. Nine studies were found regarding the following indications: tobacco addiction, anxiety and...

Daily Δ9-Tetrahydrocannabinol and Withdrawal Increase Dopamine D1-D2 Receptor Heteromer to Mediate Anhedonia- and Anxiogenic-like Behavior Through a Dynorphin and Kappa Opioid Receptor Mechanism.

Biological Psychiatry Global Open Science July 2023 Ahmed Hasbi, Bertha K. Madras, Susan R George

Frequent cannabis use is associated with a higher risk of developing cannabis use disorder and other adverse consequences. However, rodent models studying the underlying mechanisms of the reinforcing and withdrawal effects of the primary constituent of cannabis, Δ9-tetrahydrocannabinol (THC), have been limited. This study investigated the effects of daily THC (1 mg/kg, intraperitoneal, 9 days)...

Psilocybin prevents reinstatement of alcohol seeking by disrupting the reconsolidation of alcohol-related memories.

Psychopharmacology July 1, 2023 Federica Benvenuti, D Colombo, Laura Soverchia et al. 14 citations

For most psychiatric conditions, including alcohol use disorder (AUD), FDA-approved pharmacological treatments are limited and their efficacy is restricted to only certain subgroups of patients. Scientific interest in the potential of psychedelic drugs has dramatically increased because of clinical preliminary evidence of efficacy in treating various psychiatric disorders. One of the most...

The Kappa Opioid Receptor Agonist 16-Bromo Salvinorin A Has Anti-Cocaine Effects without Significant Effects on Locomotion, Food Reward, Learning and Memory, or Anxiety and Depressive-like Behaviors.

Molecules June 19, 2023 Ross Van de Wetering, Amy W M Ewald, Susan A Welsh et al.

Kappa opioid receptor (KOR) agonists have preclinical antipsychostimulant effects; however, adverse side effects have limited their therapeutic development. In this preclinical study, conducted in Sprague Dawley rats, B6-SJL mice, and non-human primates (NHPs), we evaluated the G-protein-biased analogue of salvinorin A (SalA), 16-bromo salvinorin A (16-BrSalA), for its anticocaine effects, side...

Psychedelics reopen the social reward learning critical period

Nature June 14, 2023 Romain Nardou, Young Jun Song, Noelle Wright et al. 335 citations

Abstract Psychedelics are a broad class of drugs defined by their ability to induce an altered state of consciousness 1,2 . These drugs have been used for millennia in both spiritual and medicinal contexts, and a number of recent clinical successes have spurred a renewed interest in developing psychedelic therapies 3–9 . Nevertheless, a unifying mechanism that can account for these shared...

Repeated dextromethorphan administration in adolescent rats produces long-lasting behavioral alterations.

Pharmacology, Biochemistry, and Behavior June 1, 2023 M L Shawn Bates, Keith A Trujillo

Initiation of non-medical dextromethorphan (DXM) use often occurs in adolescence, yet little is known about the consequences when use begins during this developmental period. The current experiments examined the acute response and the effects of repeated exposure to DXM in adolescence on behavior in adulthood. We examined locomotor activity, locomotor sensitization, and cognitive function, in...

Modulation of Gut Microbiome in Ecstasy/MDMA-Induced Behavioral and Biochemical Impairment in Rats and Potential of Post-Treatment with Anacyclus pyrethrum L. Aqueous Extract to Mitigate Adverse Effects.

International Journal of Molecular Sciences May 22, 2023 Abdelmounaim Baslam, Abdelfatah Aitbaba, Asmae Lamrani Hanchi et al. 16 citations

The use of illicit substances continues to pose a substantial threat to global health, affecting millions of individuals annually. Evidence suggests the existence of a 'brain-gut axis' as the involving connection between the central nervous system and gut microbiome (GM). Dysbiosis of the GM has been associated with the pathogenesis of various chronic diseases, including metabolic, malignant,...